Pfizer Inc. $PFE Shares Sold by Sound View Wealth Advisors Group LLC

Sound View Wealth Advisors Group LLC trimmed its stake in shares of Pfizer Inc. (NYSE:PFE) by 26.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 79,168 shares of the biopharmaceutical company’s stock after selling 28,453 shares during the period. Sound View Wealth Advisors Group LLC’s holdings in Pfizer were worth $1,919,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Brighton Jones LLC lifted its position in shares of Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after acquiring an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC raised its stake in Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after purchasing an additional 2,087 shares during the period. Allworth Financial LP lifted its holdings in shares of Pfizer by 14.5% in the first quarter. Allworth Financial LP now owns 152,240 shares of the biopharmaceutical company’s stock valued at $3,858,000 after purchasing an additional 19,308 shares in the last quarter. Diversify Wealth Management LLC lifted its holdings in shares of Pfizer by 6.6% in the first quarter. Diversify Wealth Management LLC now owns 11,460 shares of the biopharmaceutical company’s stock valued at $273,000 after purchasing an additional 710 shares in the last quarter. Finally, Focused Wealth Management Inc boosted its position in shares of Pfizer by 9.8% in the first quarter. Focused Wealth Management Inc now owns 105,610 shares of the biopharmaceutical company’s stock worth $2,676,000 after buying an additional 9,429 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Trading Down 1.6%

Shares of NYSE PFE opened at $24.45 on Friday. The business has a 50 day simple moving average of $24.74 and a 200 day simple moving average of $24.37. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $27.69. The stock has a market cap of $138.99 billion, a price-to-earnings ratio of 13.00, a PEG ratio of 0.81 and a beta of 0.54. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.08. The firm had revenue of $16.65 billion for the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be issued a $0.43 dividend. The ex-dividend date is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a yield of 7.0%. Pfizer’s dividend payout ratio is currently 100.00%.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. Morgan Stanley dropped their price target on Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research report on Friday, October 10th. Sanford C. Bernstein reaffirmed a “market perform” rating and set a $30.00 target price on shares of Pfizer in a research note on Friday, October 31st. Bank of America increased their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research report on Friday, October 3rd. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. Finally, Citigroup upped their price objective on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $28.18.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.